Delving into the Latest Updates on TranspoCART19(Instituto de Investigación Biomédica de Salamanca) with Synapse

Overview

Basic Info

Drug Type

Autologous CAR-T

Synonyms-

Target

CD19

Mechanism

CD19 modulators(B-lymphocyte antigen CD19 modulators)

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases

Active Indication

B-cell lymphoma recurrentB-cell lymphoma refractory

Inactive Indication-

Originator Organization

Instituto de InvestigaciÃ³n BiomÃ©dica de Salamanca - IBSAL

Active Organization

Instituto de InvestigaciÃ³n BiomÃ©dica de Salamanca - IBSAL

Inactive Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

Multicentre Phase I/IIa Study of Infusion of Autologous Peripheral Blood T Lymphocytes Expanded and Genetically Modified Using Sleeping Beauty Family Transposons to Express a Chimeric Antigenic Receptor With Anti-CD19 Specificity Conjugated to the 4-1BB Co-stimulatory Region and CD3z and huEGFRt Signal Transmission (TranspoCART19) in Patients With Relapsed or Refractory B-cell Lymphoma

The goal of this clinical trial is to to evaluate the safety and efficacy of TranspoCART19 in patients with relapsed/refractory B-lymphoma. The main questions it aims to answer are:
Maximum tolerated dose (MTD) Response rates Participants will be treated with the investigational medicinal product and will be followed for 36 months.

Start Date11 Mar 2024

Sponsor / Collaborator

Instituto de InvestigaciÃ³n BiomÃ©dica de Salamanca - IBSAL

[+3]

CTIS2024-514544-90-00 / Not yet recruitingIIT

Phase I/IIa multicentre phase I/IIa study of infusion of autologous peripheral blood T lymphocytes expanded and genetically modified using Sleeping Beauty family transposons to express a chimeric antigenic receptor with anti-CD19 specificity conjugated to the 4-1BB co-stimulatory and signal-transduction region CD3z and huEGFRt (TranspoCART19) in patients with relapsed or refractory B-cell lymphoma.

Start Date-

Sponsor / Collaborator-

100 Clinical Results associated with TranspoCART19(Instituto de Investigación Biomédica de Salamanca)

Login to view more data

100 Translational Medicine associated with TranspoCART19(Instituto de Investigación Biomédica de Salamanca)

Login to view more data

100 Patents (Medical) associated with TranspoCART19(Instituto de Investigación Biomédica de Salamanca)

Login to view more data

100 Deals associated with TranspoCART19(Instituto de Investigación Biomédica de Salamanca)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
B-cell lymphoma recurrent	Phase 2	ES	Instituto de InvestigaciÃ³n BiomÃ©dica de Salamanca - IBSAL	11 Mar 2024
B-cell lymphoma refractory	Phase 2	ES	Instituto de InvestigaciÃ³n BiomÃ©dica de Salamanca - IBSAL	11 Mar 2024